Chris Rokos and Partners Were Paid $1.2 Billion Before Hedge Fund Slid (Bloomberg)
Billionaire Chris Rokos and his partners paid themselves 914 million pounds ($1.2 billion) just before their investors suffered a record year of losses. Roughly 509.4 million pounds of that total went to Rokos himself for the year ending March 2021, the most since he started trading for his hedge fund firm, a filing with U.K.’s Companies House shows. A spokesman for Rokos Capital Management declined to comment.
Billionaires Using Bitcoin to Hedge Against Inflation (Coin Speaker)
When hedge fund manager Paul Tudor Jones bought Bitcoin in 2021, he labeled it as a way to hedge his funds against inflation. There are suggestions that the number of billionaires who invest in cryptocurrency increased in 2021 as more people seek to hedge against inflation. Many investors who were previously against Bitcoin and other cryptocurrencies as a store of value have now softened their stance.
Friday 12/31 Insider Buying Report: SVRA, THO (Nasdaq.com)
On Thursday, Savara’s Director, David A. Ramsay, made a $64,035 purchase of SVRA, buying 50,000 shares at a cost of $1.28 each. Savara is trading down about 2.3% on the day Friday. Before this latest buy, Ramsay bought SVRA on 8 other occasions during the past year, for a total cost of $1.64M at an average of $1.31 per share. And on Monday, Director Amelia Huntington purchased $50,445 worth of Thor Industries, purchasing 500 shares at a cost of $100.89 a piece. Thor Industries is trading down about 0.7% on the day Friday. So far Huntington is in the green, up about 3.5% on their purchase based on today’s trading high of $104.39.
Insider Buying: The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Independent Director Just Bought US$299k Worth Of Shares (Nasdaq.com)
Potential BridgeBio Pharma, Inc. (NASDAQ:BBIO) shareholders may wish to note that the Independent Director, Ronald Daniels, recently bought US$299k worth of stock, paying US$13.49 for each share. However, it only increased shareholding by a small percentage, and it wasn’t a huge purchase by absolute value, either. BridgeBio Pharma Insider Transactions Over The Last Year: In the last twelve months, the biggest single purchase by an insider was when Independent Director Randal Scott bought US$1.0m worth of shares at a price of US$62.50 per share.
The Chief Financial Officer of FSD Pharma (NASDAQ: HUGE) is Buying Shares (Analyst Ratings)
Today, the Chief Financial Officer of FSD Pharma (HUGE), Donal Carroll, bought shares of HUGE for $9,652. Following this transaction Donal Carroll’s holding in the company was increased by 7% to a total of $117.5K. In addition to Donal Carroll, 2 other HUGE executives reported Buy trades in the last month. Currently, FSD Pharma has an average volume of 497.35K. The company has a one-year high of $4.44 and a one-year low of $1.05. HUGE’s market cap is $42.04 million and the company has a P/E ratio of -0.92.
